Analysis of molecularly cloned DNA reveals minor differences among three virus strains of Aleutian disease of mink parvovirus

1987 ◽  
Vol 92 (1-2) ◽  
pp. 175-181 ◽  
Author(s):  
M. E. Bloom ◽  
D. Lechner ◽  
D. L. Wiedbrauk ◽  
J. B. Wolfinbarger
Keyword(s):  
Aleutian Disease Of Mink ◽  
Virus Strains

Virus Strains in This Season's Flu Vaccine Same as Last

2011 ◽  
Vol 41 (15) ◽  
pp. 25
Author(s):  
ELIZABETH MECHCATIE
Keyword(s):  
Flu Vaccine ◽  
Virus Strains

Molecular variants of IPN virus strains isolated in Japan.

1990 ◽  
Vol 25 (1) ◽  
pp. 45-46 ◽  
Author(s):  
M. SANO ◽  
N. OKAMOTO ◽  
H. FUKUDA ◽  
M. SANEYOSHI ◽  
T. SANO
Keyword(s):  
Molecular Variants ◽  
Virus Strains

Isolation and genotype analysis of spring viremia of carp virus strains from Heilongjiang Province in China

2017 ◽  
Vol 24 (5) ◽  
pp. 1141
Author(s):  
Feng JI ◽  
Jingzhuang ZHAO ◽  
Miao LIU ◽  
Wenbin HE ◽  
Jiasheng YIN ◽  
...  
Keyword(s):  
Heilongjiang Province ◽  
Genotype Analysis ◽  
Virus Strains

The identification of a novel HIV-1 second-generation recombinant form (CRF01_AE/CRF07_BC) among men who have sex with men in Jiangsu, China

2020 ◽  
Vol 18 ◽  
Author(s):  
Yin Yueqi ◽  
Zhou Ying ◽  
Lu Jing ◽  
Guo Hongxiong ◽  
Chen Jianshuang ◽  
...  
Keyword(s):  
Maximum Likelihood ◽  
Phylogenetic Trees ◽  
Second Generation ◽  
Emergency Situation ◽  
The World ◽  
Break Points ◽  
Sex With Men ◽  
Full Length Genome ◽  
Virus Strains ◽  
Hiv 1

Background: CRF01_AE and CRF07_BC are the two major HIV-1 virus strains circulating in China. The proportion of dominant subtypes (CRF01_AE and CRF07_BC) among MSM in Jiangsu province was over 80%. A large number of URFs have been found in China in recently years. Objective: This study aimed to report on novel HIV-1 recombinants. Method: We constructed Phylogenetic trees using the maximum likelihood (ML) method with 1000 bootstrap replicates in IQ-TREE 1.6.8 software and determined recombination break points using SimPlot 3.5.1. Results: We identified a novel, second-generation HIV-1 recombinant (JS020202) between CRF01_AE and CRF07_BC. The analysis of near full-length genome (NFLG) showed there were at least 8 breakpoints inner virus, which differed from any previously identified CRF and URF around the world. Conclusion: Novel diverse CRF01_AE/07_BC suggested the complexity trends of HIV-1 genetics. The emergency situation of diverse recombinant strains should be monitored continuously.

Analysis of the Receptor Specificity of Influenza A Virus Strains Using the Method of Surface Plasmon Resonance

BIOPHYSICS ◽  
2020 ◽  
Vol 65 (2) ◽  
pp. 222-224
Author(s):  
G. S. Onkhonova ◽  
P. Yu. Torzhkova ◽  
V. Yu. Marchenko ◽  
S. V. Svyatchenko ◽  
A. S. Gudymo ◽  
...  
Keyword(s):  
Surface Plasmon Resonance ◽  
Influenza A Virus ◽  
Surface Plasmon ◽  
Plasmon Resonance ◽  
Influenza A ◽  
Receptor Specificity ◽  
Virus Strains

scholarly journals A Reduced Dose Whole Virion Aluminum Adjuvanted Seasonal Influenza Vaccine Is Immunogenic, Safe, and Well Tolerated in Pediatric Patients

Viruses ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 500
Author(s):  
Zoltan Vajo ◽  
Gergely Balaton ◽  
Peter Vajo ◽  
Peter Torzsa
Keyword(s):  
Pediatric Patients ◽  
Geometric Mean ◽  
Age Groups ◽  
Aluminum Phosphate ◽  
Vaccine Virus ◽  
Serious Adverse Events ◽  
Reduced Dose ◽  
Viral Hemagglutinin ◽  
Virus Strains ◽  
Two Age Groups

Background: Data suggest that pediatric patients might react differently to influenza vaccination, both in terms of immunity and side effects. We have recently shown that using a whole virion vaccine with aluminum phosphate adjuvants, reduced dose vaccines containing 6 µg of viral hemagglutinin (HA) per strain are immunogenic, and well tolerated in adult and elderly patients. Here we show the results of a multicenter clinical trial of pediatric patients, using reduced doses of a new, whole virion, aluminum phosphate adjuvanted vaccine (FluArt, Budapest, Hungary). Methods: A total of 120 healthy volunteers were included in two age groups (3–11 years, receiving 3 µg of HA per strain, and 12–18 years, receiving 6 µg of HA per strain). We used hemagglutination inhibition testing to assess immunogenicity, based on EMA and FDA licensing criteria, including post/pre-vaccination geometric mean titer ratios, seroconversion and seropositivity rates. Safety and tolerability were assessed using CHMP guidelines. Results: All subjects entered the study and were vaccinated (ITT population). All 120 subjects attended the control visit on Day 21 (PP population). All immunogenicity licensing criteria were met in both age groups for all three vaccine virus strains. No serious adverse events were detected and the vaccine was well tolerated by both age groups. Discussion: Using a whole virion vaccine and aluminum phosphate adjuvants, a reduction in the amount of the viral hemmaglutinin is possible while maintaining immunogenicity, safety and tolerability in pediatric and adolescent patients.

Sign in / Sign up

Export Citation Format

Share Document